ArticleFrontiers in immunology2023

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.

Shuqun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.